Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

RF-Generic-Logo-sm
By Nicole Gifford & Benjamin R. Holt on November 14, 2018
Posted in Legal

RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products.

Tags: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Related Posts
 Personal Jurisdiction Over Foreign Companies that File an ANDA or aBLA in the U.S.
January 30, 2025
 Federal Circuit Reverses Decision Finding Lack of Written Description for Patent Claiming a Pharmaceutical Composition Comprising the Two Active Ingredients in Entresto®
January 28, 2025
 Federal Circuit Stays Teva v. Amneal Ruling
January 27, 2025

Blog Editors

Photo of E. Anthony FiggE. Anthony FiggMember
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • Nicole M. DeAbrantes
  • Rachel M. Echols
  • Michael Ellenberger
  • Aydin H. Harston
  • An Nguyen
  • Jennifer P. Nock
  • Gary Prato
  • Brian Rosenbloom
  • Michael Saunders
  • Andrew Stewart
  • Andrew J. Storaska
  • Vivian Tian
  • Sheena Wang

Recent Posts

  • Personal Jurisdiction Over Foreign Companies that File an ANDA or aBLA in the U.S.
  • Federal Circuit Reverses Decision Finding Lack of Written Description for Patent Claiming a Pharmaceutical Composition Comprising the Two Active Ingredients in Entresto®
  • Federal Circuit Stays Teva v. Amneal Ruling
  • How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025
  • The PREVAIL Act Could Change PTAB Trials in a Big Way

Rothwell Figg Blogs

  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Derne Street
Suite 302
Boston, MA 02114
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2025, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo